Novo Nordisk fell 18 percent in early trading on the Copenhagen Stock Exchange. The stock also plunged on the U.S. stock exchange after the report's release on Tuesday evening.
Repeated price declines, layoffs and a new CEO at the helm characterized last year for the Danish major player in diabetes treatment and weight-loss drugs.
In 2025, sales increased by 10 percent and operating profit by 6 percent. But the outlook for 2026 is not as bright. The outlook calls for negative growth of 5 to 13 percent for both sales and operating profit.
According to its financial statements, the company is also initiating a share buyback program of up to 15 billion Danish kroner.
